2-Ethenyl-5-methyl-1,3-oxazole | 1137535-52-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Ethenyl-5-methyl-1,3-oxazole
• 英文别名: 2-ethenyl-5-methyl-1,3-oxazole
• CAS: 1137535-52-4
• 化学式: C₆H₇NO
• 分子量: 109.128
• InChiKey: DXQAVMLWHWMHTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-丙炔基丙酰胺 在 gold(III) chloride 作用下， 以 二氯甲烷 为溶剂， 反应 48.0h， 生成 2-Ethenyl-5-methyl-1,3-oxazole 、 5-methylene-2-vinyl-4,5-dihydrooxazole
  参考文献：
  名称：

  Gold(III) iminophosphorane complexes as catalysts in C–C and C–O bond formations

  摘要：

  The reaction of K[AuCl4] with AgClO4 and iminophosphorane ligands (N, N-IM) Ph3P=NR [R = CH2-2-NC5H4 (1), C(O)-2-NC5H4 (2)] or Ph2PyP=NR [Py = -2-NC5H4; R = Ph (3), C(O) Ph (4)] (mol ratio 1:2.2:1) in acetonitrile affords complexes [AuCl2(N,N-IM)] ClO4 (5-8). These compounds are air- and moisture-stable and they have been evaluated in two types of catalytic processes. They have been found to be effective catalysts in the addition of 2-methylfuran or azulene to methyl vinyl ketone, as well as in the synthesis of 2,5-disubstituted oxazoles from N-propargylcarboxamides. The reactions proceed in mild conditions and with similar yields to those described for AuCl3. Using this method, oxazoles bearing a thiophene functional group 2-(2'-thienyl)-5-methylthiazole can be prepared in excellent yields. In all cases the intermediate 5-methylene-4,5-dihydroxazole can be observed by H-1 NMR. (C) 2008 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jorganchem.2008.09.058

文献信息

• [EN] HETEROARYL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLE ET UTILISATIONS ASSOCIÉES
  申请人：CELGENE AVILOMICS RES INC

  公开号：WO2014144737A1

  公开（公告）日：2014-09-18

  The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutically effective amounts of one or more of the protein kinase inhibitor compounds and methods of using said compositions in the treatment of cancers and carcinomas.

  本发明涉及作为蛋白激酶抑制剂的化合物，这些化合物在ATP结合位点包含一个半胱氨酸残基。该发明还提供了包含一种或多种蛋白激酶抑制剂化合物的药用可接受组合物，以及使用所述组合物治疗癌症和癌的方法。
• [EN] MK2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS MK2 ET UTILISATIONS ASSOCIÉES
  申请人：CELGENE AVILOMICS RES INC

  公开号：WO2014149164A1

  公开（公告）日：2014-09-25

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用方法。
• ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS
  申请人：Singh Juswinder

  公开号：US20100185419A1

  公开（公告）日：2010-07-22

  The invention is an algorithm and method for designing an inhibitor that covalently binds a target polypeptide. The algorithm and method can be used to rapidly and efficiently convert reversible inhibitors into irreversible inhibitors.

  这项发明是一种用于设计与靶多肽共价结合的抑制剂的算法和方法。该算法和方法可用于快速高效地将可逆抑制剂转化为不可逆抑制剂。
• Protein Kinase Conjugates and Inhibitors
  申请人：Celgene Avilomics Research, Inc.

  公开号：US20170174691A1

  公开（公告）日：2017-06-22

  The invention relates to protein conjugates that contain a protein kinase containing a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.

  该发明涉及含有蛋白激酶的蛋白共轭物，该蛋白激酶在ATP结合位点含有半胱氨酸残基，并且与该半胱氨酸残基共价且不可逆地结合的抑制剂，从而不可逆地抑制了蛋白激酶的活性。该发明还涉及不可逆地抑制蛋白激酶的化合物。
• ERK INHIBITORS AND USES THEREOF
  申请人：Celgene Avilomics Research, Inc.

  公开号：US20140228322A1

  公开（公告）日：2014-08-14

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用它们的方法。